Among the major areas of care fixated by people is their health. As such, advances in medicines are duly welcome and highly appreciated. Progress in research of various diseases and development of drugs to help curb them is always a good indicator. One such aspect of progress has been noted in liposomal formulation.
There has always existed the problem of ingested drugs being digested before reaching their intended target areas in the body. The process of these formulations was discovered as scientists were looking for a solution to this problem. In this solution, the drug would be closed in and protected by a layer of phospholipids and aqueous solution.
The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.
The core structure of liposomes is what causes them to be preferred among researchers of various fields and disciplines. They are formed when phospolipids are immersed in water and a specific amount of heat directed toward them. To determine if it is an appropriate carrier for a given drug, the chemical composition should be bench-marked against that of the drug, so as to avert reactions.
When such discoveries are made, researchers are eager to push it so as to find out if the new discovery can lead to better drugs. IN this case it did. An anthracycline drug known as Doxorubicin was developed to help control the spread of cancer. This is achieved by injecting stains of base DNA and RNA into the malignant cells. The enzyme topoisomerase is also injected at a later stage. These procedures inhibit replication of the cells actively controlling their growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
There has been considerable progress in the development of vaccines for diseases which do not have known cures. Such include hepatitis A, which now has a vaccine, Epaxal, under development. Inflexal V is a vaccine developed for several types of influenza especially in children. A vaccine for cancer known as Stimuvax is also in the offering.
Another point of progress thanks to this formulation has been in delivery of dietary supplements. It is still a new area under testing, but has great promise considering the level of success the formulations has garnered from targeted drug delivery. The process of the formulation is hence referred to as a new era of medical advances.
There has always existed the problem of ingested drugs being digested before reaching their intended target areas in the body. The process of these formulations was discovered as scientists were looking for a solution to this problem. In this solution, the drug would be closed in and protected by a layer of phospholipids and aqueous solution.
The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.
The core structure of liposomes is what causes them to be preferred among researchers of various fields and disciplines. They are formed when phospolipids are immersed in water and a specific amount of heat directed toward them. To determine if it is an appropriate carrier for a given drug, the chemical composition should be bench-marked against that of the drug, so as to avert reactions.
When such discoveries are made, researchers are eager to push it so as to find out if the new discovery can lead to better drugs. IN this case it did. An anthracycline drug known as Doxorubicin was developed to help control the spread of cancer. This is achieved by injecting stains of base DNA and RNA into the malignant cells. The enzyme topoisomerase is also injected at a later stage. These procedures inhibit replication of the cells actively controlling their growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
There has been considerable progress in the development of vaccines for diseases which do not have known cures. Such include hepatitis A, which now has a vaccine, Epaxal, under development. Inflexal V is a vaccine developed for several types of influenza especially in children. A vaccine for cancer known as Stimuvax is also in the offering.
Another point of progress thanks to this formulation has been in delivery of dietary supplements. It is still a new area under testing, but has great promise considering the level of success the formulations has garnered from targeted drug delivery. The process of the formulation is hence referred to as a new era of medical advances.
About the Author:
Discover the concept of liposomal formulation by reading our published blogs. To know more about the topic, visit the relevant website right now at http://purensm.com.
You already know that glutathione is the master antioxidant of the body and is produced naturally by the body itself. how does liposomal glutathione work
ReplyDelete